Hyloris Prepares For UK And Ireland Maxigesic IV Launch
Follows A Pair Of Deals To Bolster Value Added Medicines Pipeline
Value-added medicines specialist Hyloris has announced launch plans for its Maxigesic IV analgesic in the UK and Ireland after receiving approvals for the intravenous paracetamol/ibuprofen solution. The nods follow two deals aimed at bolstering the firm’s pipeline.
